Evidence map›Paper›PMID 38333207›Full record

ArticleFrontiers in immunology2024

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells.

Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhenyu WeiIntelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China.
Jiayu XuIntelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China.
Chengkui ZhaoIntelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China.
Min ZhangIntelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China.
Nan XuShanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China.
Liqing KangShanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China.
Xiaoyan LouShanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China.
Lei YuShanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China.
Weixing FengIntelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China.
Harbin Engineering University · CNEast China Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1273507.].

Indexed as

biomarkerCAR-T cell therapycytokine release syndrome (CRS)decision treeprediction

Identifiers

PMID38333207
PMCPMC10852047
OpenAlexW4391644033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.